A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors

Inclusion Criteria:

- Signed written informed consent must be obtained and documented prior to
study-specific screening procedures.

- A histologically or cytologically confirmed advanced solid tumor

- ≥ 18 years of age

- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors

- Karnofsky performance status ≥ 70%

- Male or female patients of child-producing potential must agree to use contraception
or avoidance of pregnancy measures during the study and for 30 days after
participation.

- Females of childbearing potential must have a negative serum pregnancy test.

- Laboratory results must meet study criteria.

Exclusion Criteria:

- Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
within four weeks of first infusion

- Surgery within 4 weeks prior to first infusion

- Known untreated brain metastases

- Pregnant or breastfeeding

- Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric
illness/social situations that would limit compliance with study requirements

- Other cancer within the last five years, with the exception of adequately treated
cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell
carcinoma of the skin